Objective In recent years, an increasing number of women diagnosed with malignant or non-malignant diseases have been subjected to cytotoxic chemoradiotherapy. Women who face the possibility of premature ovarian failure caused by cytotoxic therapy may retain their fertility potential via ovarian tissue cryopreservation. Despite its advantages, this fertility preservation method for women at risk of losing reproductive function is considered experimental due to 1) a possible decrease in the ovarian follicular pool as a result of cryopreservation and thawing procedures (although this has been minimised by improved methods), or by ischemic damage occurring in the graft during ovarian transplantation; and 2) the risk of minimal residual disease for cancer patients which can be defined as reintroducing pre-existing cancer cells in ovarian tissue before cryopreservation. Although the indications for ovarian cryopreservation now extend beyond cancer, cancer survivors remain as the patient population who most commonly need this procedure. For these patients, the risk of minimal residual disease is an important challenge for the application of this method. Even though the risk of reimplanting pre-existing cancer cells through ovarian transplantation is minimal or non-existent for most types of cancer, this risk must be ascertained according to cancer type and disease stage. Moreover, the efficacy of ovarian tissue transplantation is determined by the degree of success in minimising follicular loss. For this purpose, many experiments aim to reduce ischemic damage in transplanted ovarian grafts, and to determine the best methods/protocols for human ovarian cryopreservation, comparing 'slow freezing' and 'vitrification' . ( Sakarya Med J 2019, 9(1):1-10 )
Introduction
Surgical, medical, and technological developments in cancer therapies have led to improvements in quality of life and survival rates; however, preservation and maintenance of fertility are also of great importance. Women of reproductive age are at risk for a wide variety of cancer types, with breast cancer being the most frequent. Furthermore, 4,000 girls are exposed to chemotherapy (CT) and/or radiotherapy (RT) every year, which may potentially cause sterility. Over the last few decades, cancer therapy during childhood and adolescence has greatly improved survival rates. Whereas the 5-year survival rate has increased from 56% to 64% among adult women, it has increased from 56% to 75% among children. [1] [2] [3] Factors playing a role in the preservation of fertility are related to age at the time of diagnosis, type, location, and severity of cancer, and also treatment protocols received by the patient. Cancer treatment today consists mainly of conservative surgery, CT, and RT. Using these current treatment modalities in some cancer types, such as breast cancer, cure rates have exceeded 90%. However, there are very few eff ective clinical methods to preserve female fertility following aggressive CT and RT protocols. Th e adverse eff ects of chemotherapeutic agents or radiation on ovarian function are generally progressive, and mostly irreversible, leading to permanent amenorrhea and infertility. 4 Importantly, these group of patients at risk of losing reproductive function may retain their fertility potential via ovarian tissue cryopreservation. Despite its advantages, this fertility preservation method for women is considered experimental due to 1) a possible decrease in the ovarian follicular pool as a result of cryopreservation and thawing procedures (although this has been minimised by improved methods), or by ischemic damage occurring in the graft during ovarian transplantation; and 2) the risk of minimal residual disease for cancer patients which can be defi ned as reintroducing pre-existing cancer cells in ovari-an tissue before cryopreservation.
Although many cancer types do not always metastasise to the ovary, some cancers, such as leukaemia, may confer a high risk due to their systemic nature. Neuroblastoma, breast cancer, and also cancers of gastrointestinal origin may also carry a risk for micrometastasis to the ovary.
Histological evaluation of multiple ovarian tissue samples
should be performed to minimise this risk before cryopreservation. Moreover, in leukaemia and lymphoma patients, cancer cells should be screened for tumour markers (i.e. b2 microglobulin, LDH, uric acid), and immunohistochemical or other molecular analysis methods should be performed. In patients who undergo oophorectomy due to a genetic predisposition towards ovarian cancer due to mutations of tumour suppressor genes such as BRCA-1 and BRCA-2, implantation of the same tissue confers greater risk of potential future malignancy. Th is procedure is also not recommended in cases of ovarian cancer, because malignant cells might spread throughout the body again.
Methods For Fertility Preservation
Th e Ethics Committee of the American Society for Reproductive Medicine (ASRM) has approved sperm cryopreservation in men and assisted reproductive techniques (ART) in women to achieve embryo cryopreservation.5
Most fertility preservation strategies are still considered to be at an experimental stage, and do not guarantee full recovery of fertility. Current strategies and future treatment options are shown in Table 1 . 3
Cryopreservation and Transplantation of Ovarian Tissue
In women, cryopreservation of whole/cortical ovarian tissue before receiving chemo/radiotherapy, and transplantation of thawed ovarian tissue aft er full recovery is an eff ective method for preserving fertility. Th is method has advantages for the preservation of both endocrine function (i.e. regaining ovarian hormonal secretions), and reproductive function (i.e. preserving the oocyte/follicular reservoir).
Cryopreservation of ovarian tissue is a particularly promising method in the preservation of gonadal function during the prepubertal period, in that these patients do not require ovarian stimulation. A partner is not required for the procedure, and it can be applied without any delay. At the same time, the cryopreserved ovarian tissue provides a source of follicles for in vitro maturation (IVM), if necessary. Immature oocytes are smaller than mature ones, and are also more resistant to freezing and thawing procedures. Furthermore, during autotransplantation there is no need for immunosuppressive treatment.
Alkylating agents, such as chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, and ionising radiation in particular frequently lead to ovarian failure. Among paediatric cancers, in particular Hodgkin's lymphoma, Wilms tumor, B-cell nonHodgkin lymphoma (B-NHL), which are treated with RT or alkylating agents, ovarian cryopreservation can be regarded as a suitable alternative treatment. 6, 7 Aft er accumulating suffi cient experience in experimental ovarian autograft studies in animals, the same technique is now being applied in humans. 8 However, due to technical and ethical issues [ Fig. 1 ], this treatment is still considered experimental in humans, although there is a wide range of indications for ovarian tissue cryopreservation, as shown in Table 2 . 
Loss of Follicle due to Post-transplantation Ischemia
Th e second main challenge for autograft applications is the post-transplantation ischemia which reduces the lifespan of a graft , and causes massive loss of follicles in the early stages aft er transplantation. In fact, ischemia is much more detrimental to ovarian tissue than freezing/thawing injuries. 16 Although ovarian tissue is well endowed with angiogenic factors, the process of angiogenesis requires more than 48 h to revascularise a cortical slice; thus, ovarian graft s are subject to hypoxia, which leads to follicular loss. Th e survival rate of primordial follicles aft er transplantation ranges from 5% to 50%. Th ough the ovary becomes revascularised within 48 h aft er transplantation in rodents, revascularisation may occur more slowly in human ovarian graft s, as they are inherently more fi brous, with a reduced follicle density. 17 In this context, one of the most impor- Moreover, recent investigations also suggest that microvascular transplantation of cryopreserved whole ovaries may allow immediate revascularisation, ensuring better fertility preservation.
Reimplantation of the Primary Tumour
One of the most important concerns with ovarian tissue cryopreservation is the possibility of re-seeding a tumour.
Th eoretically, ovarian tissue may carry micro-metastases that could "re-infect" a patient who had been previously productive years do not metastasise to the ovaries. Th e risk of ovarian metastasis according to cancer type is shown in Table 3 .
As summarised by Sönmezer and Oktay, the cancers with high risk of ovarian involvement are leukaemia, Burkitt's lymphoma, neuroblastoma, and genital rhabdomyosarcoma. [20] [21] [22] [23] Patients with high-risk cancers should not be given the option of ovarian autotransplantation, or ovarian tissue harvest should be performed aft er the fi rst round of CT to ablate any neoplastic cells residing within the ovary. 24 However, this method of application carries a risk of diminishing the ovarian reserve with each cycle of CT.
To eliminate reimplantation of the primary tumour, alternative techniques, such as IVM of primordial follicles or ovarian tissue xenograft ing, can be applied in patients with a high risk of minimal residual disease. 25, 26 Regardless of the risk of the cancer involved, a histological assessment for micrometastases must be made on portions of the removed ovarian tissue before cryopreservation to avoid transplanting tissue that contains cancer. 27 Currently, there is no guarantee that ovarian tissue transplantation in a woman in whom the tissue was collected at the time of active cancer disease can be regarded as 100% disease-free and safe. Confi dential and simple methods to detect whether the ovarian tissue to be transplanted harbours cancer cells are urgently needed and further research is required.
Th e most frequently used in vitro methods to detect malignant cell contamination in ovarian tissue that are available for individual patients include; histology, immunohistochemistry, and detecting molecular markers using reverse transcription/quantitative polymerase chain reaction (RT/ QPCR). Although each of these methods has its individual strengths and weaknesses, none of them is perfectly suited to detect malignant cells. Histology has been validated for many years, and the use of immunohistochemistry is also prevalent. However, both methods are relatively insensitive. Immunohistochemistry is also prone to both false-negative and false-positive results. 28 Molecular markers are highly sensitive, but detecting genetic material from nonviable malignant cells that do not survive may also occur. 29 Furthermore, most tumours do not display any detectable molecular markers.
Importantly, patients should be fully aware that pieces of tissue used for graft ing cannot be fully checked for contamination with residual disease, and that safety cannot be 100% guaranteed. On the other hand, if residual ma-(C) Fresh ovarian tissue aft er graft ing. A few intact primordial and growing follicles besides many atrophic follicles were observed (x100).
(D) Frozen-thawed and graft ed ovarian tissue. Many atrophic follicles and degenerated primary follicles, besides a few intact primordial follicles are seen. Dystrophic calsifi cation and necrosis can also be noticed (x100). Generally, a cancer patient is considered disease-free aft er treatment, which may imply that malignant cells are not completely absent from the patient but only present at subclinical levels. However, the actual number of malignant cells is unknown. Th e question is therefore: how many malignant cells are necessary to cause a relapse? Again, the answer is unknown in humans for most cancers, but studies in rats have shown that just a few malignant leukemic cells are suffi cient to cause a relapse 30, 31 Th e number of malignant cells introduced back into the patient is dependent on the number of ovarian tissues transplanted. Th e number of autotransplanted tissues may vary from three fragments to more than ten, and this will clearly impact the number of malignant cells potential- ity and increased drug resistance. 32 In this context, the detection of CSCs in an ovarian graft is of great importance, and requires further investigation.
Orthotopic and/or Heterotopic

Transplantation of Ovarian Tissue
Th e most frequently applied method for cryopreservation and transplantation of ovarian tissue is reimplantation of small frozen cortical sections of ovary retrieved from the patient before initiation of cancer therapy. Aft er treatment is terminated and remission achieved, those frozen tissue specimens are thawed, and subjected to orthotopic and/or heterotopic autotransplantation. 3 
